Real World Utilisation of Raltegravir Once Daily 1200mg (RETRO Study)

Study identification

• EU PAS number:
  EUPAS30148
• Study ID:
  32479
• Official title and acronym:
  Real World Utilisation of Raltegravir Once Daily 1200mg (RETRO Study)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  This study will provide data on patient characteristics and treatment patterns of HIV positive patients initiating raltegravir 1200mg once daily (RAL OD) (2 x 600mg). These data will show how RAL OD is used in the real world setting in the UK.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Chelsea and Westminster Hospital

North Manchester Hospital Manchester

Study timelines

Date when funding contract was signed

Planned:02/07/2018

Actual:02/07/2018

Study start date

Planned:01/01/2019

Actual:01/01/2019

Data analysis start date

Planned:03/04/2019

Actual:01/04/2019

Date of final study report

Planned:30/11/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

MSD

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable